Join our
Investor Newsletter

To receive Investor News as it is released please sign up

News Releases

Stifel Nicolaus Euro - Form 8.5 (EPT/RI) - Renalytix plc

July 1, 2024
RNS Number : 5623U Stifel Nicolaus Europe Limited 01 July 2024   FORM 8.5 (EPT/RI)   PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code")   1.         KEY INFORMATION   (a) Name of

Admission of the Second Tranche Placing Shares

July 1, 2024
RNS Number : 4769U Renalytix PLC 01 July 2024   Renalytix plc ("Renalytix" or the "Company")   Admission of the Second Tranche Placing Shares   LONDON and NEW YORK -   1 July 2024   -   Renalytix plc   (NASDAQ: RNLX) (LSE: RENX)   confirms that, further to the announcements made on 12 March 2024

Form 8.3 - Renalytix plc

June 28, 2024
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1.            KEY INFORMATION (a) Full name of discloser: Pentwater Capital Management LP (b) Owner or controller of

Stifel Nicolaus Euro - Form 8.5 (EPT/RI) - Renalytix plc

June 28, 2024
RNS Number : 3407U Stifel Nicolaus Europe Limited 28 June 2024   FORM 8.5 (EPT/RI)   PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code")   1.         KEY INFORMATION   (a) Name of

Nasdaq Delisting Determination - Appeal update

June 28, 2024
RNS Number : 2544U Renalytix PLC 28 June 2024   This announcement contains inside information for the purposes of Article 7 of the UK version of Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended ("MAR").

Total Voting Rights

June 28, 2024
RNS Number : 2377U Renalytix PLC 28 June 2024     Renalytix plc ("Renalytix" or the "Company")   Total Voting Rights   LONDON  and  NEW YORK , 28 June 2024  -  Renalytix plc   (NASDAQ: RNLX) (LSE: RENX)   announces that at today's date, the Company's total issued share capital is   154,368,191

Form 8.3 - Renalytix Plc

June 27, 2024
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1.           KEY INFORMATION (a) Full name of discloser: Pentwater Capital Management LP (b) Owner or controller of

Stifel Nicolaus Euro - Form 8.5 (EPT/RI) - Renalytix plc

June 27, 2024
RNS Number : 1380U Stifel Nicolaus Europe Limited 27 June 2024   FORM 8.5 (EPT/RI)   PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code")   1.         KEY INFORMATION   (a) Name of

Form 8.3 - Renalytix Plc

June 26, 2024
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1.           KEY INFORMATION (a) Full name of discloser: Pentwater Capital Management LP (b) Owner or controller of
Displaying 41 - 50 of 605